- Home
- PGNY vs AGIO Comparison
PGNY vs AGIO Comparison
Compare PGNY & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGNY
- AGIO
- Stock Information
- Founded
- PGNY 2008
- AGIO 2007
- Country
- PGNY United States
- AGIO United States
- Employees
- PGNY N/A
- AGIO N/A
- Industry
- PGNY Misc Health and Biotechnology Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- PGNY Health Care
- AGIO Health Care
- Exchange
- PGNY Nasdaq
- AGIO Nasdaq
- Market Cap
- PGNY 1.9B
- AGIO 2.0B
- IPO Year
- PGNY 2019
- AGIO 2013
- Fundamental
- Price
- PGNY $22.98
- AGIO $28.44
- Analyst Decision
- PGNY Buy
- AGIO Buy
- Analyst Count
- PGNY 9
- AGIO 8
- Target Price
- PGNY $22.71
- AGIO $56.57
- AVG Volume (30 Days)
- PGNY 1.7M
- AGIO 634.7K
- Earning Date
- PGNY 05-08-2025
- AGIO 05-01-2025
- Dividend Yield
- PGNY N/A
- AGIO N/A
- EPS Growth
- PGNY N/A
- AGIO N/A
- EPS
- PGNY 0.57
- AGIO 11.64
- Revenue
- PGNY $1,167,221,000.00
- AGIO $36,498,000.00
- Revenue This Year
- PGNY $5.38
- AGIO $50.61
- Revenue Next Year
- PGNY $11.30
- AGIO $223.79
- P/E Ratio
- PGNY $40.51
- AGIO $2.44
- Revenue Growth
- PGNY 7.22
- AGIO 36.07
- 52 Week Low
- PGNY $13.39
- AGIO $26.66
- 52 Week High
- PGNY $36.51
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- PGNY 62.12
- AGIO 36.15
- Support Level
- PGNY $21.69
- AGIO $26.66
- Resistance Level
- PGNY $23.22
- AGIO $32.90
- Average True Range (ATR)
- PGNY 0.69
- AGIO 1.36
- MACD
- PGNY 0.21
- AGIO -0.30
- Stochastic Oscillator
- PGNY 93.12
- AGIO 28.53
About PGNY Progyny Inc.
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.